Inventor · disambiguated record
Robert George Edward Holgate
Also filed as: HOLGATE ROBERT · HOLGATE ROBERT G · HOLGATE ROBERT GEORGE E · HOLGATE ROBERT GEORGE EDWARD
26 granted patents·16 pending applications·282 citations·filing 2006–2024
96Inventor score
Top patents by PatentIndex Score
42 records- 0197US8383780B2Antibodies to TGFβGENZYME CORP·Filed 2010·Granted Feb 26, 2013·66 cites·6 claims
- 0297US7723486B2Antibodies to TGF-βOPTEIN INC·Filed 2006·Granted May 25, 2010·71 cites·14 claims
- 0395US8591901B2Antibodies to TGF-βLEDBETTER STEVEN R·Filed 2012·Granted Nov 26, 2013·50 cites·25 claims
- 0494US9481726B2Antibodies to TGF-βGENZYME CORP·Filed 2015·Granted Nov 1, 2016·7 cites·12 claims
- 0594US9090685B2Antibodies to TGF-betaGENZYME CORP·Filed 2013·Granted Jul 28, 2015·12 cites·16 claims
- 0691US9181343B2Antibody specific for CD22 and methods of use thereofREDWOOD BIOSCIENCE INC·Filed 2013·Granted Nov 10, 2015·13 cites·30 claims
- 0790US9714290B2Humanised anti CTLA-4 antibodiesJONES TIMOTHY DAVID·Filed 2012·Granted Jul 25, 2017·18 cites·19 claims
- 0888US11866509B2Humanized antibodies against CEACAM1FAMEWAVE LTD·Filed 2020·Granted Jan 9, 2024·2 cites·18 claims
- 0988US11059903B2Anti-PSMA antibodies, uses thereof and conjugates thereofPOLYTHERICS LTD·Filed 2017·Granted Jul 13, 2021·4 cites·31 claims
- 1087US9321841B2Humanised anti-CD52 antibodiesJONES TIMOTHY DAVID·Filed 2012·Granted Apr 26, 2016·11 cites·21 claims
- 1186US10874738B2Anti-CD154 antibody having improved binding, functional and safety characteristicsIMMUNEXT INC·Filed 2016·Granted Dec 29, 2020·3 cites·10 claims
- 1286US10259871B2Antibody specific for CD22 and methods of use thereofREDWOOD BIOSCIENCE INC·Filed 2015·Granted Apr 16, 2019·4 cites·30 claims
- 1385US11596689B2Methods of immunosuppression comprising administering an anti-CD154 antibodyIMMUNEXT INC·Filed 2020·Granted Mar 7, 2023·1 cites·22 claims
- 1483US2023078449A1Antibodies to TGF-BetaGENZYME CORP·Filed 2022·Application pending·0 cites
- 1582US11098130B1Antibodies and antibody fragments against the CD155 receptor and methods of use thereofNEUROSURJ RES & DEVELOPMENT LLC·Filed 2019·Granted Aug 24, 2021·6 cites·16 claims
- 1680US9988444B2Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicityPROCLARA BIOSCIENCES INC·Filed 2014·Granted Jun 5, 2018·4 cites·14 claims
- 1779US10626175B2Humanized affinity matured anti-FcRn antibodiesSYNTIMMUNE INC·Filed 2017·Granted Apr 21, 2020·2 cites·2 claims
- 1878US10550196B2Humanized antibodies against CEACAM1CCAM BIOTHERAPEUTICS LTD·Filed 2015·Granted Feb 4, 2020·3 cites·16 claims
- 1977US12116409B2Antibody specific for CD22 and methods of use thereofREDWOOD BIOSCIENCE INC·Filed 2021·Granted Oct 15, 2024·0 cites·35 claims
- 2077US11485792B2Antibodies, uses thereof and conjugates thereofPOLYTHERICS LTD·Filed 2017·Granted Nov 1, 2022·1 cites·31 claims
- 2176US10822417B2Humanized affinity matured anti-FcRn antibodiesSYNTIMMUNE INC·Filed 2017·Granted Nov 3, 2020·2 cites·9 claims
- 2276US9957317B2Humanized anti-tau antibodiesC2N DIAGNOSTICS LLC·Filed 2016·Granted May 1, 2018·2 cites·12 claims
- 2375US2021061897A1Antibodies to TGF-BetaGENZYME CORP·Filed 2020·Application pending·0 cites
- 2473US10781252B2Antibodies to TGF-βGENZYME CORP·Filed 2018·Granted Sep 22, 2020·0 cites·11 claims
- 2573US2024000929A1Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapyIMMUNEXT INC·Filed 2023·Application pending·0 cites
- 2672US2007134246A1Antibodies to TGF-BETACAMBRIDGE ANTIBODY TECH·Filed 2007·Application pending·0 cites
- 2772US2007264255A1Antibodies to TGF-betaCAMBRIDGE ANTIBODY TECH·Filed 2007·Application pending·0 cites
- 2870US2025074980A1Humanized and Affinity-Matured Anti-CEACAM1 AntibodiesTHE BRIGHAM AND WOMEN’S HOSPITAL INC·Filed 2024·Application pending·0 cites
- 2967US10174108B2Antibodies to TGF-betaGENZYME CORP·Filed 2016·Granted Jan 8, 2019·0 cites·18 claims
- 3062US11884734B2Anti-MET antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Jan 30, 2024·0 cites·16 claims
- 3162US2019352395A1Antibody specific for cd22 and methods of use thereofREDWOOD BIOSCIENCE INC·Filed 2019·Application pending·0 cites
- 3262US2024092934A1Assessment of ceacam1 expression on tumor infiltrating lymphocytesFAMEWAVE LTD·Filed 2023·Application pending·0 cites
- 3360US12173066B2Humanized and affinity-matured anti-CEACAM1 antibodiesBRIGHAM & WOMENS HOSPITAL INC·Filed 2019·Granted Dec 24, 2024·0 cites·23 claims
- 3459US2025388666A1Humanized and affinity-matured anti-ceacam1 antibodies and methods of useTHE BRIGHAM AND WOMEN’S HOSPITAL INC·Filed 2023·Application pending·0 cites
- 3559US2020207854A1HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIESSYNTIMMUNE INC·Filed 2020·Application pending·0 cites
- 3659US2020181262A1HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIESSYNTIMMUNE INC·Filed 2020·Application pending·0 cites
- 3757US11427647B2Polynucleotides encoding humanized antibodies against CEACAM1FAMEWAVE LTD·Filed 2019·Granted Aug 30, 2022·0 cites·19 claims
- 3850US2018251534A1Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicityPROCLARA BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 3950US2022056146A1Antibodies and Antigen Binding Fragments Against CD155 Methods of Use ThereofTASRIF PHARMACEUTICAL LLC·Filed 2021·Application pending·0 cites
- 4048US2010184959A1Polypeptide VariantsMEDIMMUNE LTD·Filed 2008·Application pending·0 cites
- 4148US2018057595A1Anti-MET Antibodies and Methods of Use ThereofCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4246US2018371066A1Humanized anti-tau antibodiesC2N DIAGNOSTICS LLC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert George Edward Holgate files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →